CPT 87901 HIV‑1 Genotype Reimbursement & Policy

CPT code 87901 represents a laboratory technical service that performs HIV‑1 genotypic analysis of the reverse transcriptase and protease regions from patient serum. This molecular diagnostic identifies resistance‑associated mutations that guide antiretroviral therapy selection and monitoring. As HIV treatment increasingly relies on precision genotyping to optimize outcomes and avoid drug resistance, accurate billing and coverage for this test has national significance for patients, laboratories, and payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how insurers commonly handle coverage and reimbursement for specialty molecular tests, though specific policy language and payment rates vary by contract and plan.

Readers will find a concise overview of the clinical context for HIV‑1 genotyping, common billing and coding considerations linked to the technical laboratory service, and benchmarks and policy themes relevant to payers and providers. The report summarizes payer coverage patterns, typical sites of service, and operational considerations for laboratories submitting claims for CPT code 87901. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 87901 describes a laboratory technical service that analyzes a patient specimen, typically serum, to determine the viral genotype of HIV‑1 by assessing the reverse transcriptase and protease regions. This test identifies mutations in the virus that affect antiretroviral drug susceptibility and informs clinical management of HIV infection.

Service type: Laboratory diagnostic genotyping test
Typical site of service: Clinical laboratory or reference diagnostic laboratory setting

Clinical Context

A typical patient is an adult living with HIV-1 who requires genotypic resistance testing to guide antiretroviral therapy. The patient presents for routine HIV care or for evaluation after virologic failure (rising or detectable plasma HIV-1 RNA) or suboptimal response to therapy. A blood specimen (usually plasma/serum) is collected by phlebotomy in an outpatient infectious disease clinic, HIV specialty clinic, or hospital laboratory. The specimen is sent to a reference molecular diagnostics laboratory where a laboratory analyst performs the technical testing to sequence or probe the reverse transcriptase and protease regions of the HIV-1 genome to identify resistance-associated mutations. Results are reported to the ordering clinician and used to select or modify antiretroviral regimens. Typical sites of service include outpatient clinics, hospital outpatient departments, and independent clinical laboratories performing molecular virology testing.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician or qualified professional interpretation for the test separate from the technical component.
`TC`	Technical component

Taxonomy Code	Specialty	Notes
207RH0000X	Infectious Disease	Physicians who order and interpret HIV genotypic testing.
207K00000X	Internal Medicine	Primary care physicians managing HIV patients and ordering resistance testing.
207L00000X	Pathology	Pathologists overseeing laboratory testing and result validation.
363A00000X	Clinical Laboratory	Clinical laboratory personnel and directors responsible for performing molecular diagnostics.
208000000X	Family Medicine	Family physicians who may order HIV resistance testing in outpatient settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B20`	Human immunodeficiency virus [HIV] disease	Primary diagnosis for patients with HIV-1 infection requiring genotypic resistance testing.
`Z21`	Asymptomatic human immunodeficiency virus [HIV] infection status	Used for patients known to be HIV-positive but asymptomatic; may still require baseline or surveillance genotyping.
`R77.71`	Nonspecific reaction to HIV viral load	Reflects documented abnormal viral load prompting resistance testing.
`Z11.4`	Encounter for screening for human immunodeficiency virus [HIV]	Screening encounters may lead to confirmatory and follow-up testing including resistance assays if infection confirmed.
`B97.35`	Human immunodeficiency virus 1 as the cause of diseases classified elsewhere	Used when HIV-1 is the identified causative agent in other conditions and when genotypic testing guides management.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87420`	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification (viral load)	Performed before or alongside genotypic testing to assess viral load and determine need for resistance testing.
`88290`	Microbial identification by sequencing; short read (e.g., next-generation sequencing)	May be used in laboratories employing sequencing technologies for HIV genotyping; complements `87901` technical analysis.
`86701`	Antibody; HIV-1 (includes HIV-1/HIV-2 differentiation)	Initial serologic testing for HIV infection; typically performed earlier in diagnostic workflow.
`87421`	Infectious agent detection by nucleic acid; HIV-1, quantification, amplified probe technique	Alternative viral load methodology used in monitoring that informs need for genotypic resistance testing.
`99000`	Handling and/or conveyance of specimen for transfer from physician to laboratory	Administrative/transport code sometimes billed when specimens are sent to external reference labs (use varies by payer).

OpenPayer

Summary & Overview

CPT 87901: HIV-1 Genotype Analysis of Reverse Transcriptase and Protease